Results from phase II, open-label study of anti-tumoral activity of first-line erlotinib in advanced/metastatic NSCLC patients with EGFR activating mutations, in Portugal: The MuTAR study

Barata, F. ; Queiroga, H. ; Teixeira, E. ; Almodovar, T. ; Soares, M. ; Parente, B. ; Mellidez, J.C. ; Alves, P. ; Antunes, A.

Pulmonology, 2021-03, Vol.27 (2), p.175-177 [Periódico revisado por pares]

Spain: Elsevier España, S.L.U

Texto completo disponível